Arabic Arabic English English French French German German
dark

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

Advaxis, Inc. today announced updated data from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA®. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Nearly 48,000 boosters given yesterday; 14 community cases; 34 people in hospital; two in ICU

Next Post

Ketamine and psychological therapy helped severe alcoholics abstain for longer in trial

Related Posts
Total
0
Share